Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

6H0G

Structure of the DDB1-CRBN-pomalidomide complex bound to ZNF692(ZF4)

Summary for 6H0G
Entry DOI10.2210/pdb6h0g/pdb
Related6H0F
DescriptorDNA damage-binding protein 1,DNA damage-binding protein 1,DNA damage-binding protein 1,DDB1 (DNA damage binding protein 1),DNA damage-binding protein 1,DNA damage-binding protein 1,DNA damage-binding protein 1, Protein cereblon, Zinc finger protein 692, ... (5 entities in total)
Functional Keywordse3 ubiquitin ligase, drug mediated protein-interaction, targeted protein degradation, signaling protein
Biological sourceHomo sapiens (Human)
More
Total number of polymer chains6
Total formula weight297347.78
Authors
Bunker, R.D.,Petzold, G.,Thoma, N.H. (deposition date: 2018-07-09, release date: 2018-11-07, Last modification date: 2024-01-17)
Primary citationSievers, Q.L.,Petzold, G.,Bunker, R.D.,Renneville, A.,Slabicki, M.,Liddicoat, B.J.,Abdulrahman, W.,Mikkelsen, T.,Ebert, B.L.,Thoma, N.H.
Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN.
Science, 362:-, 2018
Cited by
PubMed Abstract: The small molecules thalidomide, lenalidomide, and pomalidomide induce the ubiquitination and proteasomal degradation of the transcription factors Ikaros (IKZF1) and Aiolos (IKZF3) by recruiting a Cys-His (C2H2) zinc finger domain to Cereblon (CRBN), the substrate receptor of the CRL4 E3 ubiquitin ligase. We screened the human C2H2 zinc finger proteome for degradation in the presence of thalidomide analogs, identifying 11 zinc finger degrons. Structural and functional characterization of the C2H2 zinc finger degrons demonstrates how diverse zinc finger domains bind the permissive drug-CRBN interface. Computational zinc finger docking and biochemical analysis predict that more than 150 zinc fingers bind the drug-CRBN complex in vitro, and we show that selective zinc finger degradation can be achieved through compound modifications. Our results provide a rationale for therapeutically targeting transcription factors that were previously considered undruggable.
PubMed: 30385546
DOI: 10.1126/science.aat0572
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (4.25 Å)
Structure validation

227111

PDB entries from 2024-11-06

PDB statisticsPDBj update infoContact PDBjnumon